European Hospital highlighted Mayo Clinic’s Piero Rinaldo, M.D., Ph.D., for his discussion on how big data can help to avoid false positives in newborn screening, which he presented at the 2014 AACC Annual Meeting & Clinical Lab Expo in July.
The Dark Daily discusses why highlighting the contribution of pathology to the practice of medicine is an effective way to educate consumers, and learn about the history of certain developments, including the frozen sections technique which was pioneered at Mayo Clinic.
Recent research from the Mayo Clinic found four different assays for the detection of norovirus in stool specimens performed comparably. Researchers tested a laboratory-developed real-time polymerase chain reaction and three commercial molecular assays.
Utilizing the “frozen sections” technique, Mayo Clinic surgical and laboratory teams work together to provide patients immediate treatment by analyzing patients’ tissue samples while they are still laying on the operating table under anesthesia. In addition to helping patients, this technique cuts cost by eliminating the need for follow-up surgery when analysis finds not all the cancerous tissue has been removed.
On Monday, August 11, the Food and Drug Administration announced its approval of the first stool-based colorectal screening test co-developed by Exact Sciences and Mayo Clinic. Exact Sciences will be the sole provider of this new test. While the test is based on Mayo Clinic research, the test will not be available through Mayo Medical Laboratories.
The July article, “Tackling Reagent Lot-to-Lot Verification,” in Clinical Laboratory News, written by Alicia Algeciras-Schimnich, Ph.D., associate professor of Mayo Clinic Laboratory Medicine and Pathology and director of Mayo’s Clinical Immunoassay Laboratory, discusses the importance of reagent lot performance verification.
Eric Wieben, Ph.D., director of Mayo’s Medical Genome Facility in Rochester, Minn., discusses how Mayo Clinic is managing big data from personalized medicine in the June issue of CAP TODAY.
In the May/June issue of Medical Lab Management, Jane Hermansen, MBA, MT(ASCP), network manager for Mayo Medical Laboratories, discusses using quality assurance (QA) in the laboratory.
When standard molecular techniques fail in identifying rare and unusual tumor genetic variants, success is now being found through the use of next-generation sequencing (NGS).
A recent article in JAMA Neurology features a case report by a team of Mayo Clinic researchers that implies involvement of organs beyond the central nervous system in neuromyelitis optica spectrum disorders.
In Genetic Engineering & Biotechnology, David Smith, Ph.D., professor of laboratory medicine and pathology at the Mayo Clinic, discusses integrating and interpreting clinical genomics data.
A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL).
In the MAY Q&A Column in CAP TODAY, results from a urine collection study, conducted by the Mayo Clinic Department of Laboratory Medicine and Pathology, were referenced to respond to a reader’s question.